Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD).
Lead Product(s): SG-5-00455
Therapeutic Area: Gastroenterology Product Name: SG-5-00455
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
SG-3-06686, enhances effector T cell migration to improve the immune system’s activity against tumors and showed anti-tumor activity in preclinical models as a monotherapy and in combination with anti-Programmed Death Protein-1 (PD-1) treatment.
Lead Product(s): SG-3-06686
Therapeutic Area: Oncology Product Name: SG-3-06686
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model.
Lead Product(s): SG-5-00455
Therapeutic Area: Gastroenterology Product Name: SG-5-00455
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
SG-3-0020 enhanced PD-1 expression and IFNg secretion by anti-CD3 activated human T cells in vitro provide a strong rationale for SG-3-0020's potential future use in cancer therapies.
Lead Product(s): SG-3-0020
Therapeutic Area: Oncology Product Name: SG-3-0020
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,538.0 million Upfront Cash: $38.0 million
Deal Type: Collaboration April 06, 2020